TY - JOUR
T1 - Impact of variation in the BDNF gene on social stress sensitivity and the buffering impact of positive emotions
T2 - Replication and extension of a gene-environment interaction
AU - Van Winkel, Mark
AU - Peeters, Frenk
AU - van Winkel, Ruud
AU - Kenis, Gunter
AU - Collip, Dina
AU - Geschwind, Nicole
AU - Jacobs, Nele
AU - Derom, Catherine
AU - Thiery, Evert
AU - van Os, Jim
AU - Myin-Germeys, Inez
AU - Wichers, Marieke
PY - 2014/1/1
Y1 - 2014/1/1
N2 - A previous study reported that social stress sensitivity is moderated by the brain-derived-neurotrophic-factorVal66Met (BDNF rs6265) genotype. Additionally, positive emotions partially neutralize this moderating effect. The current study aimed to: (i) replicate in a new independent sample of subjects with residual depressive symptoms the moderating effect of BDNFVal66Met genotype on social stress sensitivity, (ii) replicate the neutralizing impact of positive emotions, (iii) extend these analyses to other variations in the BDNF gene in the new independent sample and the original sample of non-depressed individuals.Previous findings were replicated in an experience sampling method (ESM) study. Negative Affect (NA) responses to social stress were stronger in "Val/Met" carriers of BDNFVal66Met compared to "Val/Val" carriers. Positive emotions neutralized the moderating effect of BDNFVal66Met genotype on social stress sensitivity in a dose-response fashion. Finally, two of four additional BDNF SNPs (rs11030101, rs2049046) showed similar moderating effects on social stress-sensitivity across both samples. The neutralizing effect of positive emotions on the moderating effects of these two additional SNPs was found in one sample.In conclusion, ESM has important advantages in gene-environment (GxE) research and may attribute to more consistent findings in future GxE research. This study shows how the impact of BDNF genetic variation on depressive symptoms may be explained by its impact on subtle daily life responses to social stress. Further, it shows that the generation of positive affect (PA) can buffer social stress sensitivity and partially undo the genetic susceptibility.
AB - A previous study reported that social stress sensitivity is moderated by the brain-derived-neurotrophic-factorVal66Met (BDNF rs6265) genotype. Additionally, positive emotions partially neutralize this moderating effect. The current study aimed to: (i) replicate in a new independent sample of subjects with residual depressive symptoms the moderating effect of BDNFVal66Met genotype on social stress sensitivity, (ii) replicate the neutralizing impact of positive emotions, (iii) extend these analyses to other variations in the BDNF gene in the new independent sample and the original sample of non-depressed individuals.Previous findings were replicated in an experience sampling method (ESM) study. Negative Affect (NA) responses to social stress were stronger in "Val/Met" carriers of BDNFVal66Met compared to "Val/Val" carriers. Positive emotions neutralized the moderating effect of BDNFVal66Met genotype on social stress sensitivity in a dose-response fashion. Finally, two of four additional BDNF SNPs (rs11030101, rs2049046) showed similar moderating effects on social stress-sensitivity across both samples. The neutralizing effect of positive emotions on the moderating effects of these two additional SNPs was found in one sample.In conclusion, ESM has important advantages in gene-environment (GxE) research and may attribute to more consistent findings in future GxE research. This study shows how the impact of BDNF genetic variation on depressive symptoms may be explained by its impact on subtle daily life responses to social stress. Further, it shows that the generation of positive affect (PA) can buffer social stress sensitivity and partially undo the genetic susceptibility.
KW - BDNF genotype
KW - Experience sampling method (ESM)
KW - Gene-environment interaction
KW - Major depressive disorder (MDD)
KW - Positive emotions
KW - Stress sensitivity
UR - http://www.scopus.com/inward/record.url?scp=84899836645&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2014.02.005
DO - 10.1016/j.euroneuro.2014.02.005
M3 - Article
C2 - 24613654
AN - SCOPUS:84899836645
SN - 0924-977X
VL - 24
SP - 930
EP - 938
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 6
ER -